AMR Threat to National Health Systems and Economies: A Call-to-Action

November 24, 2021 / New York, USA

During World Antimicrobial Awareness Week (WAAW), the Global Coalition on Aging (GCOA) hosted a live webinar and expert panel discussion, sponsored by Merck, titled, AMR Threat to National Health Systems and Economies: A Call-to-Action. The discussion centered around two recently published reports: the 2021 AMR Preparedness Index, a first-of-its-kind report created in partnership with the Infectious Disease Society of America (IDSA) and funded by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the London School of Economics’ Developing National Strategies to Tackle Antimicrobial Resistance across Countries in the Eastern Europe, Middle East and Africa (EEMEA) Region Report, which presents in-depth analysis of national action plans (NAPs) in Egypt, Russia, and South Africa.

The session featured introductory remarks from Paul Schaper (Merck) and Gemma Buckland Merrett (Wellcome Trust) and a preview of research findings from Dr. Michael Anderson (LSE). GCOA CEO Mike Hodin moderated a panel discussion with global AMR experts James Anderson (IFPMA), Amanda Jezek (IDSA) and Danielle Peterse (CAIC) on the steps governments must take to identify and address critical gaps in their AMR policies, secure greater funding for AMR initiatives and strengthen their overall AMR governance frameworks. At a time of growing global urgency around the AMR crisis, the GCOA session called for a renewed focus on AMR governance and decisive actions at the highest levels of government.

Key takeaways from the expert discussion include:

1. AMR and aging are inextricably linked. Increased resistance disproportionately impacts older adults, who are more susceptible to drug-resistant infections. The miracle of longevity is threatened by the lack of effective antibiotics.
2. Recent efforts from global decision makers have been ineffective in reviving the drug-development pipeline for new antimicrobials. Despite consensus on the need for robust pull incentives to stimulate antimicrobial development, most countries have not taken decisive action. Multilateral organizations have also failed to take sufficient ownership over this issue.
3. Countries must better support their national action plans. While many countries have crafted National Action Plans in recent years, many lack the sufficient funding to be properly implemented
4. Long-term thinking, broader ownership needed to effectively tackle AMR. We must find alternative approaches to improving national action plans that build in robust engagement from patients, civil society, and NGO’s to help drive implementation and accountability.
5. Awareness of the AMR crisis is low. Governments, experts and civil society must do more to ensure their populations understand the risk of AMR and the need for judicious use of antimicrobials.
6. AMR remains a complex and multifaceted challenge. Recent efforts by organizations like Wellcome Trust and WHO are helping to make the issue more widely understood.
7. An all-of-the-above approach is needed to tackle AMR. A One Health approach is key to addressing AMR. Countries must simultaneously jumpstart their broken antimicrobial development pipelines, strengthen stewardship programs, reduce misuse and overprescription, bolster surveillance and monitoring programs, raise overall awareness, improve access for those who need antimicrobials, and enhance environmental safeguards.

Watch the webinar below!

 

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

GCOA Sign-on Letter to Governor Spanberger: Consequences of Importing Federal Price Caps on Virginians’ Access to Medicine & Healthy Aging Opportunities

Dear Governor Spanberger: We, the undersigned organizations, bring deep, on‑the‑ground experience serving older Americans, patients managing complex and chronic conditions, and their caregivers across Virginia and nationwide. We also have a clear understanding of which policies and programs are effective and where they fall short.

New Report Summarizes State of Expert Opinions on Japan’s Adult Vaccine Policy as Population Shifts Older

The Global Coalition on Aging (GCOA), Health and Global Policy Institute (HGPI), and the Asia-Pacific Consortium for Healthy Aging and Adult Immunization (AP-CHAAI) today announced the launch of Strengthening Vaccine Policy for Healthy Aging and Economic Growth in Japan, a landscape analysis examining the state of vaccine policy in super-aging Japan. Based on a comprehensive review of over 100 policy documents, recommendations, reports, academic papers, and gray literature articles, the report, which was funded by GSK, summarizes the latest academic research and policy discourse around adult vaccines.

WSJ Letter to the Editor: How Flu Vaccine Policies Affect the Economy

Your editorial “Vinay Prasad’s Vaccine Kill Shot” (Review & Outlook, Feb. 12) points out that a recent decision by Mr. Prasad, the leader of the Food and Drug Administration’s vaccine division, will have negative consequences. Mr. Prasad’s decision to reject Moderna’s flu vaccine without even reviewing it is even worse than you describe. Denying us a new, innovative flu vaccine is horrible health policy. Innovation is at risk because, as Moderna’s CEO has said, if the largest market is off limits, investments won’t be made. But the decision will also have economic consequences. Investment in preventive health is critical as our population ages. In its April 2025 World Economic Outlook report, the International Monetary Fund dedicated an entire chapter to the need for healthier longevity as the global population ages.

Joe Biden’s ‘Cancer Moonshot’ May be Derailed by New Policies, Including His Own

For almost a decade, President Biden has championed a bold “cancer moonshot” — an initiative he first launched in 2016, revived early in his administration, and reiterated during this year’s State of the Union. It is a laudable goal, especially for an aging nation where cancer and chronic disease are on the rise. There’s just one problem: Recent federal and state policies are poised to derail the incredible progress made in oncology since 2016. A rash of policies now threatens to limit access and slow progress towards new breakthroughs.

Global Coalition on Aging, Leading G7 Government Officials, Call for Incentivized Antibiotic Innovation

The Global Coalition on Aging (GCOA), in partnership with the Japanese Pharmaceutical Manufacturer’s Association (JPMA), and public health leaders call on G7 governments to fund pull incentives and make “fair share” investments in antibiotic innovation to fight the global antimicrobial resistance (AMR) crisis. GCOA, JPMA, and health and government officials from the European Union, Italy, Japan, and United Kingdom recently convened to discuss how G7 countries must respond. GCOA today published a report detailing takeaways from the closed-door meeting, “The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development Through a Pull Incentive: Challenges and Collaboration.”

Kishida and Biden Face a Similar Demographic Crisis

Your front page story “Japan wrestles with age-old problem as population declines at record rate” (Report, April 13) and the letter in the same edition from Tim Hill, “A gently declining population is no reason to panic”, both describe what all societies face as they modernise in the 21st century.

2024 AMR Preparedness Index Progress Report Highlights Urgent Need For Global Action Against Antimicrobial Resistance

Today, the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the 2024 AMR Preparedness Index Progress Report. Released in the lead up to the United Nations General Assembly 2024 High-level Meeting on Antimicrobial Resistance (AMR) this September, the 2024 Progress Report assesses how the eleven largest global economies have advanced on calls to action laid out in the 2021 AMR Preparedness Index.

New Global Analysis Across Five Cities Shows Inequities in Adult Immunization Uptake, Signaling Need to Redesign Local and National Policy Interventions

GSK, in collaboration with the Global Coalition on Aging (GCOA), announced a new report from the IQVIA Institute for Human Data Science (IQVIA Institute). The report, funded by GSK, explores the role of social and structural determinants of health in adult vaccine access and uptake across five global cities with strong data about their aging populations: Bangkok, Thailand; Brussels, Belgium; Chicago, US; Manchester, United Kingdom; and New York City, US.